Development of CDK4/6 Inhibitors in Gastrointestinal Cancers: Biomarkers to Move Forward
1Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics, Iowa City, IA 52242, USA.
Abstract:
Targeting the cell cycle has become a focus of cancer research bearing impressive results with the introduction of CDK4/6 inhibitors in the treatment of ER-positive/HER2-negative breast cancers. However, no definitive benefit in other cancers has been observed. In gastrointestinal cancers, despite preclinical studies pinpointing positive effects on cancer inhibition in pre-clinical models, no positive clinical trials have been published with CDK4/6 inhibitors. Several biomarkers have been proposed in breast cancers, where the field is more advanced, and include up-regulations of the inhibited kinases CDK4 and CDK6 and their partner cyclin D as well as the main target of phosphorylation, RB. Up-regulation of Cyclin E, an E2F1/RB regulated gene, also arises as a marker of CDK4/6 inhibition resistance. Signaling from receptor tyrosine kinase pathways through KRAS/BRAF/MEK and PI3K/AKT/mTOR are also implicated in feedback CDK4/6 activation and inhibitors resistance. In gastrointestinal cancers, some of these biomarkers have also proven valuable in predicting sensitivity to CDK4/6 inhibitors and would lead markers to guide clinical development. Modulation of the tumor microenvironment, where immune cells are prominent components, arises as a feature of CDK4/6 inhibition and could be harnessed in therapeutic combinations.
Insights
CDK4/6 inhibitors show promise in breast cancer but not yet in gastrointestinal cancers. Biomarkers are key to predicting response and guiding future clinical development for these cell cycle drugs.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- Targeting the cell cycle, specifically CDK4/6, has yielded success in ER-positive/HER2-negative breast cancer.
- CDK4/6 inhibitors have not yet demonstrated definitive clinical benefits in other cancer types, including gastrointestinal cancers, despite promising preclinical data.
Purpose of the Study:
- To review the role of CDK4/6 inhibitors in cancer treatment.
- To identify biomarkers for predicting sensitivity and resistance to CDK4/6 inhibitors.
- To explore the potential of CDK4/6 inhibitors in gastrointestinal cancers and combination therapies.
Main Methods:
- Literature review of preclinical and clinical studies on CDK4/6 inhibitors.
- Analysis of biomarkers associated with CDK4/6 pathway and resistance mechanisms.
- Examination of tumor microenvironment modulation by CDK4/6 inhibition.
Main Results:
- Biomarkers such as CDK4/6, cyclin D, RB, and Cyclin E up-regulation are implicated in breast cancer response and resistance.
- Signaling pathways (RAS/RAF/MEK, PI3K/AKT/mTOR) influence CDK4/6 activity and resistance.
- Some biomarkers show potential for guiding CDK4/6 inhibitor development in gastrointestinal cancers.
Conclusions:
- CDK4/6 inhibitors are effective in specific breast cancer subtypes but require further investigation in gastrointestinal cancers.
- Biomarker identification is crucial for optimizing CDK4/6 inhibitor therapy and clinical trial design.
- Modulation of the tumor microenvironment by CDK4/6 inhibitors presents opportunities for novel combination therapies.
Related Concept Videos
02:34Inhibition of Cdk Activity
02:15M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:39Positive Regulator Molecules